Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2021-03-31 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2020年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2020 年年度报告全文" which translates to "2020 Annual Report Full Text" for 健帆生物科技集团股份有限公司 (Jafron Biomedical Co., Ltd.). It contains detailed sections typical of an annual report, including company overview, financial data, business summary, management discussion, governance, and financial statements. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial data, management statements, and comprehensive business descriptions. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-03-31 Chinese
2020年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2020 年年度报告摘要" which translates to "2020 Annual Report Summary". It contains detailed financial data for the year 2020, including revenue, net profit, earnings per share, and other financial indicators. It also discusses the company's business operations, products, market position, and strategic outlook for the year. The document is lengthy (15,000 characters) and includes comprehensive financial and operational information typical of an annual report. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2020
2021-03-31 Chinese
2020年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for the fiscal year 2020 of 健帆生物科技集团股份有限公司. It contains detailed audit opinions, basis for audit opinions, key audit matters such as revenue recognition and goodwill impairment testing, and extensive financial statements including consolidated and company balance sheets, income statements, and cash flow statements. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the document fits the category of Audit Report / Information (AR). FY 2020
2021-03-31 Chinese
2020年度独立董事述职报告（周凌宏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2020" from a specific independent director of the company. It details the director's attendance at board and shareholder meetings, participation in board committees, independent opinions on various board matters, on-site investigations, investor protection efforts, training, and other related activities during the year 2020. The content is a detailed report on the director's duties and activities rather than a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on management/board activities and governance oversight. This fits best under the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document length is 3738 characters, which is substantive but not a full annual report or financial report. Therefore, the classification is MANG with high confidence.
2021-03-31 Chinese
2020年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2020 by 健帆生物科技集团股份有限公司. It discusses the company's internal control evaluation, including financial and non-financial internal control defects, control environment, control procedures, internal audit, governance structure, and compliance with relevant laws and regulations. The document is detailed and contains substantive information about the company's internal control systems and their effectiveness. It is not an announcement or a brief summary but a comprehensive report on internal control self-assessment. This type of document fits best under the category of Audit Report / Information (AR), as it relates to internal control evaluation and audit-related information rather than a full annual report or other categories. FY 2020
2021-03-31 Chinese
2020年度独立董事述职报告（杨柏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2020" from a company, detailing the independent director's attendance at board and shareholder meetings, opinions on various board matters, participation in committees, and activities related to governance and oversight during the year 2020. It is a detailed report on the independent director's duties and opinions rather than a general annual report or financial statement. The content focuses on governance and director responsibilities rather than financial results or audit opinions alone. This type of document fits best under Board/Management Information (MANG), as it relates to board member activities and governance reporting. The document length is 3699 characters, which is relatively short but contains substantive content about board activities and independent director opinions, not just an announcement or certification. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2021-03-31 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.